Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood
; 140(17): 1845-1857, 2022 10 27.
Article
in En
| MEDLINE
| ID: mdl-35917453
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Azacitidine
/
Leukemia, Myeloid, Acute
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Guideline
Limits:
Adult
/
Aged
/
Humans
Language:
En
Journal:
Blood
Year:
2022
Document type:
Article
Country of publication:
Estados Unidos